227 related articles for article (PubMed ID: 11829464)
1. Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels.
Takeuchi T; Tsutsumi O
Biochem Biophys Res Commun; 2002 Feb; 291(1):76-8. PubMed ID: 11829464
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
3. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction.
Takeuchi T; Tsutsumi O; Ikezuki Y; Takai Y; Taketani Y
Endocr J; 2004 Apr; 51(2):165-9. PubMed ID: 15118266
[TBL] [Abstract][Full Text] [Related]
4. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
[TBL] [Abstract][Full Text] [Related]
5. [Relations of serum adipocyte fatty acid binding protein to sex hormone and lipoproteins in patients with polycystic ovary syndrome].
Hu WH; Qiao J; Li R; Wang LN
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(45):3186-9. PubMed ID: 17313783
[TBL] [Abstract][Full Text] [Related]
6. Prolactin levels in the polycystic ovary syndrome.
Milewicz A
J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
[TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
8. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
9. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS.
Kandaraki E; Chatzigeorgiou A; Livadas S; Palioura E; Economou F; Koutsilieris M; Palimeri S; Panidis D; Diamanti-Kandarakis E
J Clin Endocrinol Metab; 2011 Mar; 96(3):E480-4. PubMed ID: 21193545
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS).
Pinhas-Hamiel O; Singer S; Pilpel N; Koren I; Boyko V; Hemi R; Pariente C; Kanety H
Clin Endocrinol (Oxf); 2009 Dec; 71(6):823-7. PubMed ID: 19389110
[TBL] [Abstract][Full Text] [Related]
11. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
12. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
13. The androgenic profile of women with non-insulin-dependent diabetes mellitus.
Tok EC; Ertunc D; Evruke C; Dilek S
J Reprod Med; 2004 Sep; 49(9):746-52. PubMed ID: 15493567
[TBL] [Abstract][Full Text] [Related]
14. Androgen and SHBG serum concentrations in late post-menopause women.
Skałba P; Wójtowicz M; Sikora J
Med Sci Monit; 2003 Mar; 9(3):CR152-6. PubMed ID: 12640346
[TBL] [Abstract][Full Text] [Related]
15. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls.
Panidis D; Farmakiotis D; Koliakos G; Rousso D; Kourtis A; Katsikis I; Asteriadis C; Karayannis V; Diamanti-Kandarakis E
Hum Reprod; 2005 Aug; 20(8):2127-32. PubMed ID: 15890737
[TBL] [Abstract][Full Text] [Related]
17. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.
Uncu G; Sözer MC; Develioğlu O; Cengiz C
Gynecol Endocrinol; 2002 Dec; 16(6):447-52. PubMed ID: 12626031
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biochemical hyperandrogenemia and body mass index in women presenting with amenorrhea.
Cupisti S; Dittrich R; Binder H; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 May; 115(5):298-302. PubMed ID: 17516292
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of 3alpha-androstanediol glucuronide in young women with polycystic ovary syndrome, idiopathic hirsutism and in normal subjects.
Meczekalski B; Slopien R; Warenik-Szymankiewicz A
Eur J Obstet Gynecol Reprod Biol; 2007 May; 132(1):88-92. PubMed ID: 16979812
[TBL] [Abstract][Full Text] [Related]
20. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
